|
Volumn 18, Issue 9, 2007, Pages 1582-1583
|
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib [3]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIINFECTIVE AGENT;
CAPECITABINE;
COMPLEMENT COMPONENT C3;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ERLOTINIB;
FIBRINOGEN;
GEMCITABINE;
PREDNISOLONE;
AGED;
ALLERGIC VASCULITIS;
CASE REPORT;
CHEMOEMBOLIZATION;
DRUG DOSE REDUCTION;
DRUG ERUPTION;
DRUG WITHDRAWAL;
FEMALE;
HEMIHEPATECTOMY;
HISTIOCYTOSIS;
HUMAN;
HUMAN TISSUE;
IMMUNOFLUORESCENCE TEST;
INFLAMMATORY INFILTRATE;
LETTER;
LEUKOCYTOCLASTIC VASCULITIS;
LIVER CELL CARCINOMA;
MALE;
NEUTROPHIL CHEMOTAXIS;
OUTCOME ASSESSMENT;
PANCREAS ADENOCARCINOMA;
PRIORITY JOURNAL;
PURPURA;
SKIN DEFECT;
SKIN NECROSIS;
TREATMENT DURATION;
TREATMENT REFUSAL;
ADENOCARCINOMA;
ADMINISTRATION, ORAL;
AGED;
ANTINEOPLASTIC AGENTS;
CARCINOMA, HEPATOCELLULAR;
FEMALE;
HUMANS;
LEG;
LIVER NEOPLASMS;
MALE;
MIDDLE AGED;
PANCREATIC NEOPLASMS;
QUINAZOLINES;
VASCULITIS, HYPERSENSITIVITY;
|
EID: 34548395965
PISSN: 09237534
EISSN: 15698041
Source Type: Journal
DOI: 10.1093/annonc/mdm420 Document Type: Letter |
Times cited : (22)
|
References (5)
|